c-FLIP expression in colorectal carcinomas: Association with Fas/FasL expression and prognostic implications

Histopathology

Volumn 51, Issue 2, 2007, Pages 150-156

  Korkolopoulou, P ^a   Saetta, A A ^a   Levidou, G ^a   Gigelou, F ^a   Lazaris, A ^a   Thymara, I ^a   Scliri, M ^a   Bousboukea, K ^a   Michalopoulos, N V ^a   Apostolikas, N ^a   Konstantinidou, A ^a   Tzivras, M ^a   Patsouris, E ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

c FLIP; Colorectal carcinoma; Fas; FasL; Immunohistochemistry

Indexed keywords

DEATH RECEPTOR; FAS LIGAND; FLICE INHIBITORY PROTEIN; PARAFFIN;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER STAGING; CELL DEATH; COLORECTAL CARCINOMA; FEMALE; HAZARD RATIO; HUMAN; HUMAN TISSUE; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD95; APOPTOSIS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; COLORECTAL NEOPLASMS; FAS LIGAND PROTEIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 34447515452     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2007.02723.x     Document Type: Article

References (28)

1. Jackel MC. Genetic control of programmed cell death (apoptosis). Prospects for biological tumour staging? HNO 1998 46 614 625.
2. Itoh N, Yonehara S, Ishii A et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991 66 233 243.
3. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumour necrosis factor family. Cell 1993 75 1169 1177.
4. Strand S, Hofmann WJ, Hug H et al. Lymphocytic apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumour cells. A mechanism of immune evasion? Nat. Med. 1996 2 1361 1366.
5. Scaffidi C, Schmitz I, Krammer PH, Peter ME. The role of c-FLIP in modulation of CD95-induced apoptosis. J. Biol. Chem. 1999 274 1541 1548.
6. Irmler M, Thome M, Hahne M et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997 388 190 195.
7. Korkolopoulou P, Goudopoulou A, Voutsinas G et al. c-FLIP expression in bladder urothelial carcinomas: its role in resistance to Fas-mediated apoptosis and clinicopathologic correlations. Urology 2004 63 1198 1204.
8. Bullani RR, Huard B, Viard-Leveugle I et al. Selective expression of FLIP in malignant melanocytic skin lesions. J. Invest. Dermatol. 2001 117 360 364.
9. Ryu BK, Lee MG, Chi SG, Kim YW, Park JH. Increased expression of c-FLIP (L) in colonic adenocarcinomas. J. Pathol. 2001 194 15 19.
10. Lee SH, Kim SH, Kim SY et al. Increased expression of FLIP, an inhibitor of Fas-mediated apoptosis, in stomach cancer. APMIS 2003 111 309 314.
11. Thomas RK, Kallenborn A, Wickenhauser C et al. Constitutive expression of c-FLIP in Hodgkin and Reed-Sternberg cells. Am. J. Pathol. 2002 160 1521 1528.
12. O'Connell J, Houston A, Bennett MW, O'Sullivan GC, Shanahan F. Altered mechanisms of apoptosis in colon cancer: Fas resistance and counterattack in the tumour-immune conflict. Ann. NY Acad. Sci. 2000 910 178 192.
13. Bennett MW, O'Connell J, Houston A et al. Fas ligand upregulation is an early event in colonic carcinogenesis. J. Clin. Pathol. 2001 54 598 604.
14. Ito Y, Monden M, Takeda T et al. The status of Fas and Fas ligand expression can predict recurrence of hepatocellular carcinoma. Br. J. Cancer 2000 82 1211 1217.
15. Frankel B, Longo SL, Ryken TC. Human astrocytomas co-expressing Fas and Fas ligand also produce TGFβ2 and Bcl-2. J. Neuro-Oncol. 1999 44 205 212.
16. Zhu Q, Liu JY, Xu HW et al. Mechanism of counterattack of colorectal cancer cell by Fas/Fas ligand system. World J. Gastroenterol. 2005 1161 25 29.
17. Wang Q, Wang X, Zhou Y, Evers BM. PKC delta-mediated regulation of FLIP expression in human colon cancer cells. Int. J. Cancer 2006 118 326 334.
18. Galligan L, Longley DB, McEwan M, Wilson TR, McLaughlin K, Johnston PG. Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP. Mol. Cancer Ther. 2005 4 2026 2036.
19. Giannopoulou I, Nakopoulou L, Zervas A et al. Immunohistochemical study of pro-apoptotic factors Bax, Fas and CPP32 in urinary bladder cancer: prognostic implications. Urol. Res. 2002 30 342 345.
20. Korkolopoulou P, Lazaris AC, Konstantinidou A-E et al. Differential expression of bcl-2 family proteins in bladder carcinomas. Relationship with apoptotic rate and survival. Eur. Urol. 2002 41 274 283.
21. Pitti RM, Marsters SA, Lawrence DA et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 1998 396 699 703.
22. Sato T, Irie S, Kitada S et al. FAP-1: a protein tyrosine phosphatase that associates with Fas. Science 1995 268 411 415.
23. Tamm I, Kornblau SM, Segall H et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin. Cancer Res. 2000 6 1796 1803.
24. Ryan AE, Shanahan F, O'Connell J, Houston AM. Fas ligand promotes tumour immune evasion of colon cancer in vivo. Cell Cycle 2006 5 246 249.
25. Nozoe T, Yasuda M, Honda M, Inutsuka S, Korenaga D. Fas ligand expression is correlated with metastasis in colorectal carcinoma. Oncology 2003 65 83 88.
26. Ryan AE, Lane S, Shanahan F, O'Connell J, Houston A. Addressing the 'Fas counterattack' controversy: blocking Fas ligand expression suppresses tumour immune evasion of colon cancer in vivo. Cancer Res. 2005 65 9817 9823.
27. Kataoka T, Budd RC, Holler N et al. The caspase-8 inhibitor FLIP promotes activation of NF-kappaB and Erk signaling pathways. Curr. Biol. 2000 10 640 648 M, Screpanti V, Catrina AI, Bogen B, Biberfeld P, Grandien A. The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumour progression factors. J. Exp. Med. 1999 190 1025 1032.
28. Strater J, Hinz U, Hasel C et al. Impaired CD95 expression predisposes for recurrence in curatively resected colon carcinoma: clinical evidence for immunoselection and CD95L mediated control of minimal residual disease. Gut 2005 54 661 665.